JP2003530340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003530340A5 JP2003530340A5 JP2001574079A JP2001574079A JP2003530340A5 JP 2003530340 A5 JP2003530340 A5 JP 2003530340A5 JP 2001574079 A JP2001574079 A JP 2001574079A JP 2001574079 A JP2001574079 A JP 2001574079A JP 2003530340 A5 JP2003530340 A5 JP 2003530340A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- solid
- triglycerides
- oleic
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000011859 microparticle Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- -1 sodium alkyl aryl sulfonate Chemical class 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-N sodium;dodecyl sulfate;hydron Chemical compound [H+].[Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-N 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0008785.8 | 2000-04-10 | ||
| GBGB0008785.8A GB0008785D0 (en) | 2000-04-10 | 2000-04-10 | Organic compounds |
| PCT/EP2001/004051 WO2001076561A2 (en) | 2000-04-10 | 2001-04-09 | Pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003530340A JP2003530340A (ja) | 2003-10-14 |
| JP2003530340A5 true JP2003530340A5 (https=) | 2008-05-22 |
Family
ID=9889585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001574079A Pending JP2003530340A (ja) | 2000-04-10 | 2001-04-09 | 医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20030133984A1 (https=) |
| EP (2) | EP1767193A3 (https=) |
| JP (1) | JP2003530340A (https=) |
| CN (2) | CN1231208C (https=) |
| AU (1) | AU2001250420A1 (https=) |
| BR (1) | BR0109931A (https=) |
| CA (1) | CA2404368C (https=) |
| FR (1) | FR2807658A1 (https=) |
| GB (1) | GB0008785D0 (https=) |
| IT (1) | ITMI20010748A1 (https=) |
| PE (1) | PE20020225A1 (https=) |
| WO (1) | WO2001076561A2 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
| AR033711A1 (es) * | 2001-05-09 | 2004-01-07 | Novartis Ag | Composiciones farmaceuticas |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| JP4387639B2 (ja) * | 2002-07-16 | 2009-12-16 | 久光製薬株式会社 | 経皮吸収製剤 |
| GB2391471B (en) * | 2002-08-02 | 2005-05-04 | Satishchandra Punambhai Patel | Pharmaceutical compositions |
| GB0218996D0 (en) * | 2002-08-14 | 2002-09-25 | Novartis Ag | Organic compounds |
| AU2003205543A1 (en) * | 2003-01-14 | 2004-08-10 | Lifecycle Pharma A/S | Dry dispersions |
| US20040185068A1 (en) * | 2003-03-18 | 2004-09-23 | Zhi-Jian Yu | Self-emulsifying compositions, methods of use and preparation |
| CN1829514A (zh) * | 2003-07-25 | 2006-09-06 | 惠氏公司 | Cci－779冻干制剂 |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| GB0504950D0 (en) * | 2005-03-10 | 2005-04-20 | Novartis Ag | Organic compositions |
| US7276476B2 (en) * | 2005-07-13 | 2007-10-02 | Allergan, Inc. | Cyclosporin compositions |
| US7288520B2 (en) * | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
| US20070015691A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
| US7297679B2 (en) * | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
| US7202209B2 (en) | 2005-07-13 | 2007-04-10 | Allergan, Inc. | Cyclosporin compositions |
| US20070015693A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
| US7501393B2 (en) | 2005-07-27 | 2009-03-10 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
| US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
| EP1880715A1 (en) * | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
| WO2008109163A1 (en) * | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc. | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| CN101199836B (zh) * | 2007-11-07 | 2011-03-30 | 安徽省药物研究所 | 一种阶段释放型环孢素a固体微乳制剂及其微乳固化方法 |
| CU23892B1 (es) * | 2007-12-07 | 2013-04-19 | Ct De Investigación Y Desarrollo De Medicamentos Cidem | Composición farmacéutica microencapsulada de ciclosporina a |
| CN102223875A (zh) * | 2008-11-21 | 2011-10-19 | 贝林格尔.英格海姆国际有限公司 | 口服给药的强效hcv抑制剂的药物组合物 |
| JP5607736B2 (ja) | 2009-07-07 | 2014-10-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎ウイルスプロテアーゼ阻害剤のための医薬組成物 |
| US20110105387A1 (en) * | 2009-09-19 | 2011-05-05 | Nian Wu | Method of treatment with rapamycin |
| EA027666B1 (ru) | 2010-05-03 | 2017-08-31 | ТЕИКОКУ ФАРМА ЮСЭй, ИНК. | Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| TW201503912A (zh) * | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物 |
| HK1245095A1 (zh) | 2015-05-20 | 2018-08-24 | Novartis Ag | 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合 |
| ITUA20164228A1 (it) * | 2016-06-09 | 2017-12-09 | Labomar S R L | Formulazione a matrice grassa auto-emulsionante e gastro-resistente e relativo metodo di preparazione |
| CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| WO2025153584A1 (en) * | 2024-01-17 | 2025-07-24 | Basf Se | Solid self-emulsifying dosage form |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1274354A (fr) | 1956-03-10 | 1961-10-27 | Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol | |
| US3244592A (en) | 1962-06-09 | 1966-04-05 | Arai Tadashi | Ascomycin and process for its production |
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| AU609242B2 (en) * | 1988-01-29 | 1991-04-26 | Novartis Ag | Cyclosporin compositions |
| GB2222770B (en) | 1988-09-16 | 1992-07-29 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporins |
| DK0427680T3 (da) | 1989-11-09 | 1995-12-18 | Sandoz Ltd | Heteroatom-holdige cykliske forbindelser |
| MY110418A (en) | 1990-07-02 | 1998-05-30 | Novartis Ag | Heteroatoms-containing tricyclic compounds. |
| PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| WO1992007552A1 (fr) * | 1990-11-06 | 1992-05-14 | Nippon Shinyaku Co., Ltd. | Preparation lyophilisee et sa production |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| GB9113872D0 (en) | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
| HUT66531A (en) | 1992-05-07 | 1994-12-28 | Sandoz Ag | Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5234140A (en) | 1992-07-28 | 1993-08-10 | S. C. Johnson & Son, Inc. | Re-useable aerosol container |
| US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| WO1995014023A1 (en) | 1993-11-19 | 1995-05-26 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| KR0146671B1 (ko) * | 1994-02-25 | 1998-08-17 | 김충환 | 사이클로스포린-함유 분말 조성물 |
| ES2270426T3 (es) * | 1994-03-18 | 2007-04-01 | Supernus Pharmaceuticals, Inc. | Sistema de suministros de farmacos emulsionados. |
| JP2936209B2 (ja) * | 1994-06-01 | 1999-08-23 | ユーハン コーポレーション | サイクロスポリン含有組成物およびその製造方法 |
| PE52896A1 (es) | 1994-10-26 | 1996-12-12 | Novartis Ag | Composicion farmaceutica |
| US5716642A (en) * | 1995-01-10 | 1998-02-10 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents |
| DE19544507B4 (de) * | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin enthaltende Präparate |
| US6306434B1 (en) * | 1997-02-12 | 2001-10-23 | Chong Kun Dang Corp. | Pharmaceutical composition comprising cyclosporin solid-state microemulsion |
| NZ328751A (en) * | 1997-09-16 | 1999-01-28 | Bernard Charles Sherman | Solid medicament containing an anionic surfactant and cyclosporin |
| ID25908A (id) * | 1998-03-06 | 2000-11-09 | Novartis Ag | Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida |
| US20030216303A1 (en) * | 1998-03-06 | 2003-11-20 | Michael Ambuhl | Emulsion preconcentrates containing cyclosporin or a macrolide |
| DE19819273A1 (de) * | 1998-04-30 | 1999-11-11 | Pharmatec International S Giul | Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung |
| KR100336090B1 (ko) * | 1998-06-27 | 2002-05-27 | 윤승원 | 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제 |
| EP2127642A3 (en) * | 1998-08-13 | 2010-02-24 | Cima Labs, Inc. | Microemulsions as solid dosage forms for oral administration |
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| AU1043201A (en) * | 1999-11-02 | 2001-05-14 | Cipla Limited | Cyclosporin formulation |
| GB0009773D0 (en) * | 2000-04-19 | 2000-06-07 | Univ Cardiff | Particulate composition |
-
2000
- 2000-04-10 GB GBGB0008785.8A patent/GB0008785D0/en not_active Ceased
-
2001
- 2001-04-06 IT IT2001MI000748A patent/ITMI20010748A1/it unknown
- 2001-04-06 FR FR0104713A patent/FR2807658A1/fr not_active Withdrawn
- 2001-04-06 PE PE2001000321A patent/PE20020225A1/es not_active Application Discontinuation
- 2001-04-09 CA CA2404368A patent/CA2404368C/en not_active Expired - Fee Related
- 2001-04-09 AU AU2001250420A patent/AU2001250420A1/en not_active Abandoned
- 2001-04-09 JP JP2001574079A patent/JP2003530340A/ja active Pending
- 2001-04-09 US US10/239,456 patent/US20030133984A1/en not_active Abandoned
- 2001-04-09 EP EP06120628A patent/EP1767193A3/en not_active Withdrawn
- 2001-04-09 EP EP01923719A patent/EP1272163A2/en not_active Ceased
- 2001-04-09 BR BR0109931-0A patent/BR0109931A/pt not_active Application Discontinuation
- 2001-04-09 CN CNB01807863XA patent/CN1231208C/zh not_active Expired - Fee Related
- 2001-04-09 WO PCT/EP2001/004051 patent/WO2001076561A2/en not_active Ceased
- 2001-04-09 CN CNB2005100643755A patent/CN100431600C/zh not_active Expired - Fee Related
-
2005
- 2005-12-14 US US11/300,575 patent/US20060134203A1/en not_active Abandoned
-
2010
- 2010-05-05 US US12/774,452 patent/US20100215734A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003530340A5 (https=) | ||
| CN101396334B (zh) | 姜黄素脂质载体及其制备方法 | |
| Beg et al. | Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers | |
| US8821932B2 (en) | Pharmaceutical compositions | |
| CA2533013A1 (en) | Controlled release preparations | |
| JP2002509877A5 (https=) | ||
| Singh et al. | A Comparison between Use of Spray and Freeze Drying Techniques for Preparation of Solid Self‐Microemulsifying Formulation of Valsartan and In Vitro and In Vivo Evaluation | |
| Chan et al. | Microencapsulation of oils using sodium alginate | |
| CA2446798A1 (en) | Solid pharmaceutical compositions comprising cyclosporin | |
| AU2014350208B2 (en) | Multi-particulate drug delivery system | |
| Chow et al. | A study of the mechanisms of wet spherical agglomeration of pharmaceutical powders | |
| JPH0533095B2 (https=) | ||
| HU211930A9 (en) | Pharmaceutical capsules containing ranitidine | |
| CN101444486B (zh) | 一种水溶性药物缓释微球及其制备方法和应用 | |
| FR2740357A1 (fr) | Granules redispersables dans l'eau comprenant une matiere active sous forme liquide et un tensio-actif non ionique du type alcoxyles | |
| JP3783031B2 (ja) | 軟ろう粉末をカプセル化する方法およびそれによって製造される軟ろう粉末 | |
| Revathi et al. | Self-emulsifying drug delivery system: A review | |
| JP2012501305A (ja) | 医薬組成物に関連する改善 | |
| JP5297194B2 (ja) | 初期溶解率が改善されたプランルカスト固体分散体の薬剤学的組成物およびその製造方法 | |
| EP1058540B1 (fr) | Pellet oral a liberation immediate comprenant des glycerides polyglycolyses, procede de fabrication | |
| Yahaya et al. | Development and characterization of self-nano emulsifying drug delivery system of ibuprofen | |
| Patra | Solid lipid-based delivery system for oral delivery of drugs: A review | |
| Yadav et al. | An insight to self emulsifying drug delivery systems, their applications and importance in novel drug delivery | |
| Patel et al. | Formulation development and evaluation of lipid based nanoparticles of valsartan by microemulsification | |
| Kane et al. | A STATISTICAL MIXTURE DESIGN APPROACH FOR FORMULATING POORLY SOLUBLE COMPOUNDS IN LIQUID FILLED HARD SHELL CAPSULE |